Xenetic Biosciences (XBIO) Asset Writedowns and Impairment (2015 - 2020)
Xenetic Biosciences' (XBIO) quarterly Asset Writedowns and Impairment came in at $9.2 million in Q3 2020, up 181.51% YoY from $3.3 million in Q4 2019, and up 181.51% on a QoQ basis from $3.3 million in Q3 2019.
Xenetic Biosciences (XBIO) Asset Writedowns and Impairment (2015 - 2020) Analysis & Trends
Xenetic Biosciences (XBIO) has 4 years of Asset Writedowns and Impairment data on file, last reported at $9.2 million in Q3 2020.
- Quarterly Asset Writedowns and Impairment rose 181.51% year-over-year to $9.2 million in Q3 2020, while the trailing twelve-month figure through Dec 2021 was $9.2 million (down 26.21% YoY) and the FY2020 annual result came in at $9.2 million, up 181.51% from the prior year.
- Asset Writedowns and Impairment climbed to $9.2 million in Q3 2020, from $3.3 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $9.2 million in Q3 2020 to a low of $5768.0 in Q4 2016.
- A 3-year average of $2.1 million and a median of $71464.5 in 2016 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2016 — Asset Writedowns and Impairment slumped 92.59% — and 2020, when it jumped 181.51%.
- Tracing XBIO's Asset Writedowns and Impairment over 3 years: stood at $5768.0 in 2016, then soared by 56824.05% to $3.3 million in 2019, then jumped by 181.51% to $9.2 million in 2020.
- The last three Asset Writedowns and Impairment figures came in at $9.2 million (Q3 2020), $3.3 million (Q3 2019), and $5768.0 (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 9.24 Mn |
| Sep 30, 2020 | 9.24 Mn |
| Sep 30, 2019 | 3.28 Mn |
| Sep 30, 2019 | 3.28 Mn |
| Dec 31, 2016 | 5,768.00 |
| Dec 31, 2016 | 5,768.00 |
| Sep 30, 2016 | 25,822.00 |
| Sep 30, 2016 | 25,822.00 |
| Jun 30, 2016 | 38,169.00 |
| Jun 30, 2016 | 38,169.00 |
| Mar 31, 2016 | 104,760.00 |
| Mar 31, 2016 | 104,760.00 |
| Dec 31, 2015 | 77,856.00 |
| Dec 31, 2015 | 77,856.00 |
| Sep 30, 2015 | 75,935.00 |
| Sep 30, 2015 | 75,935.00 |